Insight Molecular Diagnostics Inc. income statement

In fiscal 2025, Insight Molecular Diagnostics Inc. reported revenue of $4.1m, up 115.6% on the year before, operating income of −$51.1m (a -1260.8% margin) and net income of −$50.2m, or −$1.65 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Insight Molecular Diagnostics Inc.: income statement, annual
Fiscal year	2015Dec 2015	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Revenue	0	1	2	1	2	2	4	2
Cost of revenue	—	2	1	1	1	1	2	1
Gross profit	—	−1	1	−0	0	1	2	1
Research and development	5	10	5	7	9	10	16	19
Selling and marketing	0	6	1	1	3	4	6	8
General and administrative	4	17	22	22	11	10	11	11
Operating income	−9	−30	−54	−18	−25	−61	−51	−50
Interest expense	0	—	—	—	—	—	—	—
Net interest income	−0	−0	−0	−0	−0	−0	−0	−0
Income before tax	—	−31	−53	−19	−25	−61	—	—
Income tax	—	−1	−9	—	0	0	0	0
Net income	−9	−30	−64	−73	−28	−61	−50	−49
Diluted EPS	−$0.14	−$0.46	−$0.72	−$13.25	−$3.75	−$4.66	−$1.65	−$1.46
Diluted shares (average)	63m	65m	89m	6m	8m	13m	30m	34m
EBITDA	−9	−29	−53	−16	−23	−59	−49	−48

US$ millions unless shown otherwise. Fiscal quarters.

Insight Molecular Diagnostics Inc.: income statement, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Revenue	0	1	2	1	0	1	0	0
Cost of revenue	0	1	1	0	0	1	0	0
Gross profit	0	1	1	0	0	0	0	0
Research and development	3	2	3	3	4	6	5	4
Selling and marketing	1	1	1	1	1	2	2	2
General and administrative	3	3	3	3	3	2	3	3
Operating income	−14	−34	−7	−10	−11	−23	−4	−11
Net interest income	−0	−0	−0	−0	−0	−0	−0	−0
Income before tax	−13	−34	—	—	—	—	—	—
Income tax	0	0	0	0	0	0	0	0
Net income	−13	−34	−7	−10	−11	−23	−4	−11
Diluted EPS	−$0.98	−$2.30	−$0.26	−$0.30	−$0.34	−$0.74	−$0.12	−$0.31
EBITDA	−13	−33	−6	−9	−10	−23	−4	−11

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: ICU vs IMDX FEMY vs IMDX IMDX vs PLSE

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Insight Molecular Diagnostics Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Insight Molecular Diagnostics Inc.